Archives in Cancer Research

  • ISSN: 2254-6081
  • Journal h-index: 14
  • Journal CiteScore: 3.77
  • Journal Impact Factor: 4.09
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • J-Gate
  • Secret Search Engine Labs
  • International Committee of Medical Journal Editors (ICMJE)
  • Zenodo
Share This Page

Review - (2023) Volume 11, Issue 2

Challenges in Bladder Carcinoma Treatment and Immunotherapy's Future Bladder Cancer: Current Challenges and Future Directions

Christophe Daniel*
Department of Experimental and Clinical Biomedical, Italy
*Correspondence: Christophe Daniel, Department of Experimental and Clinical Biomedical, Italy, Email:

Received: 30-Jan-2023, Manuscript No. ipacr-23-13452; Editor assigned: 01-Feb-2023, Pre QC No. ipacr-23-13452 (PQ); Reviewed: 15-Feb-2023, QC No. ipacr-23-13452; Revised: 20-Feb-2023, Manuscript No. ipacr-23-13452 (R); Published: 27-Feb-2023, DOI: 10.36648/2254-6081- 11.2-151


One of the most prevalent urological cancers with a variety of forms is bladder carcinoma. About 90% of transitional cell cancer is caused by it (TCC). Non-muscle invasive bladder carcinoma (NMIBC) and muscle-invasive bladder carcinoma are the two subtypes of TCC according to histopathology (MIBC). NMIBC makes up around 75% of bladder cancer cases with recent diagnoses. These tumours are limited to the bladder's mucosal or submucosal area. A sizable portion of NMIBC turns into MIBC, raising the mortality rate. Recurrence rates for bladder cancer range from 50 to 70%, and 15% of these cases have a greater likelihood of developing into MIBC. Nearly a quarter of bladder carcinoma patients have the disease already spread to the bladder muscle wall when they are detected (i.e., MIBCs). The recommended course of therapy for bladder cancer essentially consists of two approaches: if the muscular layers remain unaffected, the bladder is spared and only receives a few resection procedures. While under bad circumstances, bladder removal is necessary.

The most frequent cancer of the urinary tract and one of the most common cancers worldwide is bladder cancer (BCa). Despite the fact that for many years the clinical approach to BCa was largely unaltered, recent research has opened the door to a new era in the diagnosis and treatment of the condition. BCa-specific mortality began to diminish in areas with a variety of efforts that raised public knowledge of the risk factors and reduced exposure to carcinogens. Transurethral surgery is being refined by the urologic community to use more exacting and superior methods. For individuals who previously underwent radical cystectomy because to BCG failure, new medications have been licenced. The breadth and therapeutic usefulness of lymphadenectomy are currently under intense scrutiny in randomised studies, despite the fact that total bladder removal remains the gold standard for the treatment of muscle-invasive malignancy. To improve the possibility of full treatment administration and positive oncological outcomes, alternatives to perioperative chemotherapy have been emerged. Last but not least, advances in molecular biology and our comprehension of carcinogenesis herald the dawn of customised therapeutics for bladder cancer. The status and future directions in the epidemiology, diagnosis, and treatment of bladder cancer are in-depth explored in the current review [1-5].


BCG failure; Perioperative chemotherapy; Surgical treatment; Urinary bladder cancer


The most popular method of treating bladder cancer is transurethral resection of bladder tumours (TURBT). Usually, it is treated when there are obvious tumour masses in the bladder epithelium. Flexible cystoscopy is used to remove the tumour while under the influence of regional or general anaesthesia. It also gives samples for diagnostic investigations. For TURBT to have a good prediction, it must be accurate and comprehensive. Additionally, TURBT is linked to discomfort and mild bleeding. When a high-grade or T1 tumour has been discovered following an imperfect resection, a second resection is taken into consideration. The choice of therapy and treatment is mostly based on the individual circumstances of the patient and the level of risk that the patient and the urologist are willing to accept. For the patients' better prognosis, adjuvant treatment is frequently taken into consideration.

An immediate chemotherapeutic instillation following TURBT has been shown to dramatically lower the recurrence rate. Due to the significant risk of progression involved, an intermediate instillation is necessary for individuals who have a greater chance of recurrence. Adjuvant chemotherapy combined with TURBT has been found to slow recurrence rates rather than progression. For individuals with advanced bladder cancer, combined chemotherapy based on cisplatin is the chosen first treatment. It has been demonstrated that the cisplatin-based therapy increase median survival to 12–15 months and 5-year survival to about 15%. Gemcitabine with cisplatin or methotrexate, vinblastine, doxorubicin, and cisplatin are still the recommended first-line treatments. However, for patients who relapse following firstline treatment, the prognosis is typically dismal. High-grade, invasive bladder cancer is often treated with radical cystectomy and bilateral pelvic lymphadenectomy. However, a radical cystectomy is a significant abdominal operation that comes with a long recovery period and a high risk of complications after surgery. Patients with MIBCs are frequently advised to undergo radiotherapy.

Any of the several cancers that develop in the tissues of the bladder are referred to as bladder cancer. Blood in the pee, urinating pain, and low back pain are all symptoms. It is brought on when the bladder's lining epithelial cells develop into cancer. Smoking, a family history of the disease, radiation therapy in the past, recurrent urinary tract infections, and exposure to specific chemicals are all risk factors for bladder cancer. Cancer of the transitional cell type is the most prevalent kind. Squamous cell carcinoma and adenocarcinoma are further kinds. The usual method of diagnosis is cystoscopy with tissue biopsies. Medical imaging and transurethral resection are used to stage the malignancy.

The cancer's stage determines the course of treatment. Surgery, radiation therapy, chemotherapy, or immunotherapy may all be used in some combination. Transurethral resection, partial or total bladder removal, and urine diversion are all possible surgical procedures. In the United States, Canada, and Europe, the average five-year survival rates are 77%, 75%, and 68%, respectively. As of 2018, there were 549,000 new instances of bladder cancer worldwide, resulting in 200,000 fatalities. The most common age of onset is between 65 and 84. Males are afflicted more frequently than females. Southern and Western Europe had the highest incidence of bladder cancer in 2018, followed by North America with rates of 15, 13, and 12 cases per 100,000 individuals. Northern Africa and Western Asia had the greatest mortality rates from bladder cancer, followed by Southern Europe.


The most frequent cancer in the urinary tract is still bladder cancer (BCa). 549,393 persons with BCa in 2018, and 199,922 died from the illness worldwide. Age-standardized incidence (ASIR), which exhibits significant regional variation, is expected to keep increasing over the course of the following ten years. There were shown to be several risk factors for BCa. The risk differs between genders and is significantly influenced by exposure to a number of carcinogens, with cigarette smoking being the most common one. This is in addition to geography and age. Age-standardized mortality rates (ASMR) have begun to fall in affluent nations, while rising in low-income regions of the world.

Either microscopic or extensive hematuria is the main indication of BCa. Urothelial bladder cancer (UBC) restricted to the mucosa (NMIBCa—non-muscle invasive disease) is diagnosed in 75% of instances if the bladder tumour is found. In the remaining 25– 30% of patients, BCa has already metastasized or entered deeper bladder wall layers (MIBCa—muscle-invasive disease). Patients with NMIBCa typically have transurethral resection of the bladder tumour (TURBT), whereas patients with MIBCa typically undergo radical cystectomy (RC). Intravesical instillations are added during TURBT in a few patients to stop progression and recurrence. The long-term survival rates of patients with UBC have remained constant for decades despite several surgical and anesthesiological advancements as well as widespread use of perioperative chemotherapy. At the same time, cutting-edge molecular research has significantly improved our understanding of the biology of disease. It is anticipated that personalised therapy, together with various improvements in surgical methods and cutting-edge intravesical as well as systemic treatment modalities, will improve the oncological results of our patients. With regard to bladder cancer epidemiology and management, a few issues and impending views are provided and evaluated in this study [6-10].

Symptoms and signs: Evidence Gathering

Blood in the urine is a common symptom of bladder cancer and may be visible or only detected under a microscope. The most prevalent and painless sign of bladder cancer is blood in the urine. Visible blood in the urine might only be present for a short time, so a urine test might be necessary to confirm the presence of non-visible blood. Between 80 and 90 percent of bladder cancer patients first displayed visible blood. Other illnesses, such as bladder or ureteric stones, infection, kidney disease, kidney malignancies, or vascular malformations, may also result in blood in the urine, though these conditions (with the exception of kidney cancers) would normally be uncomfortable. Other signs could be pain when urinating, frequent urination, or having the urge to urinate but being unable to. These warning signs and symptoms are not exclusive to bladder cancer; they can also be brought on by non-cancerous illnesses such cystitis, overactive bladder, and prostate infections. Urine that has mucin secreted from some uncommon bladder cancers, such as urachal adenocarcinoma, causes it to be thick.

A non-systematic search of the PubMed database was done to find recent English-language papers that addressed current problems and possible solutions. During the search, the following words and phrases were used: bladder cancer or urothelial cancer, along with various keyword groupings pertinent to the parts under discussion. The following were some of them: biology, aetiology, epidemiology, management, and results. All abstracts were evaluated, clinical series, review articles, and editorials were located, but only the most important works were thoroughly examined and cited.


According to WHO statistics, there are large regional variations in the incidence of BCa, with age-standardized rates in more developed places being nearly three times higher than in less developed nations (9.5 vs. 3.3). The variety is one of several things that are thought to be caused by differences in smoking, obesity, drinking, and eating too much red meat. Smoking continues to be the greatest risk factor for BCa despite the fact that the risk is complex. According to estimates, it causes half of all BCa cases, with the severity of the damages varying with the amount and frequency of smoking. According to a recent investigation, there are high connections between cigarette use and both BCa incidence and mortality, but these are mostly shown in men rather than women. The WHO has issued a warning regarding the high prevalence of cigarette smoking and the aforementioned risk factors throughout the European countries, and has also suggested a number of crucial initiatives that policy-makers should put into place to decrease exposure. The most significant ones, among many others, are raising prices for cigarettes and alcohol, banning smoking in public places, increasing the visibility of fruits and vegetables in supermarkets, encouraging cycling as the most practical mode of transportation, promoting physical activity through various means, such as using stairs instead of elevators in attractive buildings, and restricting food consumption. Although tobacco use is decreasing globally, it seems unlikely that most nations will meet the 30% reduction goal established by the WHO Global Action Plan for the Prevention and Control of Non communicable Diseases 2013-2020 by 2025. In the interim, a gradual decline in BCa-specific mortality is finally followed by a decline in cigarette smoking prevalence in European nations. However, the fall is not simply attributable to the decline in the prevalence of smoking; it is also due to the better and quicker access to high-quality medical treatment that has resulted in the early discovery of potentially fatal diseases. According to analysis of the incidence of BCa over the past few years in high-income nations, there has been a drop in BCa-specific mortality and an increase in BCa incidence.


Despite using traditional cisplatin-based treatment, bladder cancer has a poor prognosis. More target discoveries are therefore urgently required in order to treat bladder cancer with individualised and precise therapy. Significant progress has recently been achieved in this area, and several innovative molecular-targeted drugs are being tested in clinical trials to suppress immunological checkpoints, VEGF/R, FGF/R, or EGF/R. A successful tailored therapy for bladder cancer would undoubtedly result from the ongoing studies testing immune checkpoint inhibitors, overcoming immunological tolerance utilising modified T cell therapy, or identifying new antigens using next-generation sequencing. Targeted medicines, chemotherapy, and immunotherapy together might change future medical care. These combined medicines would be an important treatment plan for bladder cancer. Our understanding of the biology of the illness has improved thanks to improvements in bladder cancer diagnosis and treatment. The number of newly diagnosed advanced cases will decrease as a result of increased social awareness of risk factors, reduced work exposure, and attentive illness diagnosis. Radical cystectomies will become less common as a result of high-quality transurethral procedures combined with adjuvant medications that are more effective and less morbid. Finally, systemic therapy will be tailored based on the molecular picture of advanced disease provided by cutting-edge technology. The management of bladder cancer will necessitate ongoing collaboration between ranges of medical specialties in order to produce a successful outcome.


  1. Gonzalez MS, Sugarbaker PH (2004) Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding. Br J Surg 91: 304-311.
  2. Indexed at, Google Scholar, Crossref

  3. Shubhada D, Sugarbaker P (2006) Update on the surgical approach to mucocele of the appendix. J Am Coll Surg 202: 680-684.
  4. Indexed at, Google Scholar, Crossref

  5. Kiran K T, Pappas S, Clark G (2013) Right hemicolectomy for mucinous adenocarcinoma of the appendix: just right or too much?. Ann Surg Oncol 20: 1063-1067.
  6. Indexed at, Google Scholar, Crossref

  7. Mark AV, Reetesh KP (2018) An update on the diagnosis, grading, and staging of appendiceal mucinous neoplasms. Adv Anat Pathol 25: 38-60.
  8. Indexed at, Google Scholar, Crossref

  9. Sugarbaker PH (2017) When and when not to perform a right colon resection with mucinous appendiceal neoplasms. Ann Surg Oncol 24: 729-732.
  10. Indexed at, Google Scholar, Crossref

  11. Joseph M, Rhonda KY, Fiona MG, Ulysses JB, Robert HY (2003) Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases. Am J Surg Pathol 27: 1089-1103.
  12. Indexed at, Google Scholar, Crossref

  13. Sugarbaker HP (2006) New standard of care for appendiceal epithelial malignancies and pseudomyxoma peritonei syndrome. Lancet Oncol 7: 69-76.
  14. Indexed at, Google Scholar, Crossref

  15. Sugarbaker HP (2009) Epithelial appendiceal neoplasms. Cancer J 15: 225-235.
  16. Indexed at, Google Scholar, Crossref

  17. Petr B, František A, Pavel V, Josef M, Kopic J (2019) Pseudomyxoma peritonei syndrome. Adv Surg 30:  233-280.
  18. Indexed at, Google Scholar, Crossref

  19. Riaz AA, Thomas F, Catrin S, Ginimol M, Ahmed K, et al. (2020) The SCARE 2020 guideline: updating consensus Surgical CAse REport (SCARE) guidelines. Int J Surg 84: 226-230.
  20. Indexed at, Google Scholar, Crossref

Citation: Daniel C (2023) Challenges in Bladder Carcinoma Treatment and Immunotherapy's Future Bladder Cancer: Current Challenges and Future Directions. Archives Can Res, Vol.11 No. 2: 108.